

令和元年6月10日現在

機関番号：16101

研究種目：基盤研究(C) (一般)

研究期間：2016～2018

課題番号：16K10428

研究課題名(和文)胆管構造を有する機能的肝組織再構築に関する研究

研究課題名(英文)Functional liver tissue rebuilding with bile duct structure on heterotopic transplantation

研究代表者

森根 裕二(MORINE, Yuji)

徳島大学・大学院医歯薬学研究部(医学域)・准教授

研究者番号：60398021

交付決定額(研究期間全体)：(直接経費) 3,600,000円

研究成果の概要(和文)：ホモジネート肝組織の異所性移植(腸管粘膜下)における脂肪組織由来幹細胞(ADRC)の肝細胞機能維持や肝構成細胞(特に胆管細胞)分化の可能性を検討した。肝組織移植はADRCとの共移植により肝機能保護効果・肝細胞分化を示したが、胆管などの肝構成細胞への分化は認めず、共移植前のADRC分化誘導が必要と考えられた。また3次元培養システムも単離肝細胞保護効果を有し、ADRCとの併用に期待が持たれた。

研究成果の学術的意義や社会的意義

本研究ではADRC・3次元培養システムを活用した異所性肝移植の長期安定化や胆管構築を伴った機能的異所性肝組織再構築の可能性について検討した。残念ながら、ADRCの肝細胞機能維持は確認されたが、胆管細胞分化・組織再構築までの結果を得ることはできず、胆管構造を有する組織再構築には、課題が残ったが、3次元培養システムの可能性や肝組織再構築手法の方向性を示すことはできたと思われる。

研究成果の概要(英文)：The purpose of this study was to establish the procedure of functional liver tissue rebuilding with bile duct structure on heterotopic liver tissue transplantation using adipose-derived regenerative cells (ADRC) and 3D culture system.

We demonstrated the protective effect of ADRC for transplant liver function and the differentiation to hepatocyte like cell, but not the ability to differentiate along multiple lineage pathways for other liver component cell from ADRC. Therefore, the pre-induction protocol of ADRC towards cholangiocyte seemed to be necessary before the combined transplantation. Also, 3D culture system indicated the protective effect of primary hepatocyte culture. But, we could not establish the optimal protocol of cholangiocyte differentiation from ADRC, yet. Consequently, while there were some future problems, the possibility of 3D culture system on liver tissue transplantation and the directionality of liver tissue rebuilding approach could be indicated in this study.

研究分野：医歯薬学、外科系臨床医学、外科学一般

キーワード：異所性肝移植 ADRC 胆管細胞 3次元培養

activin TGF-β supergene family
follistatin bD5%

Hepatogastroenterol. 2005,
□ H20~21

2007 □ (□) B8 Surg Today. 2013 5% 27AS
□ 5) 7VMk5bKs8M2 □
□ %2v=CT6MC+SKPK □
(+Y2byPMS(+2(;K(+8)
mesenchymal regenerative cell □ ADRC □ 8S(+5%)
Res. 2013, J Hepatobiliary Pancreat Sci. 2014 □ □
KD5%2v)E)FKAS □ H25~27 %%2 □ C □ K(+bsbjDcY
PM/8mMBN82A(+uS))S(□) □
M06 □

SHH8 □
□ H20~21
K359×KkR □
)P □
adipose tissue-derived
□ H22~24 %%2 □ C) J Surg
Epigenetics □
K+M PM □
C □ K(+bsbjDcY

rN) (+b8 □
AS804)w, 8BKSI+` (+M) Y 6+ w □
+b □ □ Transpl Int. 2014 □ 6+g) bvb □
6S) % TM550 #4: 450 □
K4% KS(0 (+b) □

□ X9 □
homogenize KS) □
□

2v88 □ □ Liver Int. 2014 □ K(4) b6×%TbE □
d) □ □ 6× □ % KS □)S(bm2x+4:4)cg18 □
8) fS □ (+vX □ (+%2E(+M6%+(+ □
□ +P18 □ %PMd(+b+09bs6 □
K)p bHW M(+k(+1b(+bES0b) □
vb(+7x □ d)E □ (#+b) SB(+1b(+ □
)S(1%) 2°bgbm2X8ckg188fS □ (+ □
/bd88b)I(Mbs □ □ J Exp Clin Cancer Res. 2000 □ □
(+ (+gM d))Mc(1R □
b5; M6 □ □ K(4)E □ +b+X89M □
(+c(+g □ Mv □ MU4) □




図1: 3D培養を用いた異索性肝組織+ADRC移植の可能性

E □ TNF-α □ T (+ □
b68x8v □ wM □ □ J Cell
Mol Med. 2009 □ □ ADRC b) Trophic □
X8(+b □ cell-cell contact □ - □
b8 □ VEGF □ ADRC (□
8G(KS) □ J Hepatobiliary Pancreat
Sci. 2014 □ GbG □ □ ADRC E □
x+(+8(+ □
1b(+7(+1v □
K+d(+1bGcG □
rbd(+be810A □
+v8 □ □ %26KS □
□ 1 □ □

0)%2b% □
)7VxE(MxM2ybSuDIb □
(+DpPK%218(+bsbjDc □
YPM/8mMBN82A(+uS))S(□) □
1M06fSd)8vd)6×) □
S(bm2cg188 □
%2E □ homogenize KS(+ □ ADRC □
SB(+1(+1b(□ b+ □
□ OM □ □ (+wde □
□ d) □ □ 6× □ □ □
S(S(+d))S(b □
+X8 □ OM □





図2: 消化管粘膜下への肝組織+ADRC移植モデルの作成

1%) □ 2b2 □
(1) + (+) □
+ADRC □
e) □ ADRC b □
+OMGKS □ 7 □ 8 4K □ SD □
□ 70%) 7V □ □ .k/v □ 20min □

+ADRC1x10⁵ 1ml 27Gy 58 1ml i) ii) iii) PK55%~70% 6067

(2) + isolation ADRC b 8 4K SD 5mm 67x 2mM EDTA+PBS 30min Medium Vd PBS 42° Cell strainerde Small intestinal crypt FACS stemness marker M

(3) 3D culture primary hepatocyte 7 8 4K C57BL/6J 0.05M 0.06 mg/mL collagenase 50 g, 3 min at 4°C x 2 2D culture 6well plate 1x10⁵ 3D culture 96well U plate CellSai FUJIFILM 3 8 0.1mg/ml 1x10⁵ viability 806M




図3 : ADRC-hepatocyte like cell 分化プロトコール

(4) ADRC 40,000cells/cm² 6-well plate days 8 Step 1: Day1~2; serum-free DMEM/F-12 medium, Day3; DMEM/F-12 containing 2 μM GSK3 inhibitors Chir99021 0.5 mg/mL albumin fraction V, Day4~5; DMEM/F-12 containing 1% ITS 0.5 mg/mL albumin fraction V Step 2: Day6~10; MEM/NEAA containing 1% ITS 0.5 mg/mL albumin fraction V 20ng/ml BMP2 30ng/ml FGF4 Step 3: Day11~15; MEM/NEAA containing 1% ITS 0.5 mg/mL albumin fraction V 20ng/ml HGF Day11~15: MEM/NEAA containing 1% ITS 0.5 mg/mL albumin fraction V 20ng/ml HGF 10ng/ml OSM 10-6M Dexamethasone +/% Definitive endoderm: DE Hepatocyte like cell 806

2%2B (1) +ADRC 14 4 ADRC CSFE +ADRC vKCC ADRC +ADRC Lb ADRC 5 ADRC +ADRC 8 ADRC +ADRC




図4 : 臓器粘膜(被膜)下への肝組織移植モデル(移植14days)




図10 : ADRC-hepatocyte like cell 分化プロトコル




図11 : ADRC-hepatocyte like cell 分化・機能評価

ADRC b(+) (IMvb(+bSB(+b(1)) S(+N ADRC b (ISIKC06S) S 3D culture GMGE)56x2ME S ADRC bGD)

ADRC (+MGE) S(c) k 018KGIS

3 216 7\$1e8E 12 6

D Ikemoto T, Morine Y, Imura S, Saito Y, H 4 % H. The protective effect of epigallocatechin 3-gallate on mouse pancreatic islets via the Nrf2 pathway. *Surg Today*. 2019 ;49(6):536-545.1 w doi: 10.1007/s00595-019-1761-0.

D Yamada S, Shimada M, Morine Y, Imura S, Ikemoto T HI0 p 3 % H. A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging. *PLoS One*. 2019 25;14(1):e0210579. 1w . doi: 10.1002/ags3.12058.

D! Saito Y, Morine Y, Iwahashi S, Ikemoto T, Imura S, Yamanaka-Okumura H, Hirayama A, Soga T, Tomita M, Shimada M. Changes of liver metabolites following hepatectomy with ischemia reperfusion towards liver regeneration. *Ann Gastroenterol Surg*. 2018 30;2(3):204-211. 1w

D" Feng R, Morine Y, Ikemoto T, Imura S, Iwahashi S, Saito Y, Shimada M. Photobiomodulation with red light-emitting diodes accelerates hepatocyte proliferation through reactive oxygen species/extracellular signal-regulated kinase pathway. *Hepato Res*. 2018;48(11):926-936. 1w . doi: 10.1111/hepr.13182.

D□ Ikemoto T, Feng R, Shimada M, Saito Y, Iwahashi S, Morine Y, Imura S. A New 2-Step Acceleration Protocol Using a Histone Deacetylase Inhibitor to Generate Insulin-Producing Cells From Adipose-Derived Mesenchymal Stem Cells. *Pancreas*. 2018;47(4):477-481. 1w . doi: 10.1097/MPA.0000000000001017.

D□ Yada K, Morine Y, Ishibashi H, Mori H, Shimada M. Treatment strategy for successful hepatic resection of icteric liver. *J Med Invest*. 2018;65(1.2):37-42. 1w . doi: 10.2152/jmi.65.37.

D% Morine Y, H 4 % H. Major liver resection reduces nonprotein respiratory quotient and increases nonesterified fatty acid at postoperative day 14 in patients with hepatocellular carcinoma. *Clin Nutr ESPEN*. 2018;23:194-199. 1w . doi: 10.1016/j.clnesp.2017.10.001.

x Morine Y, Shimada M, Ikemoto T, Arakawa Y, Iwahashi S, Saito Y, Yamada S, Imura S. Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma. *Anticancer Res*. 2017;37(11):6421-6428. 1w . DOI: 10.21873/anticancer.12096

D' Saito Y, Morine Y, Shimada M. Mechanism of impairment on liver regeneration in elderly patients: Role of hepatic stellate cell function. *Hepato Res*. 2017;47(6):505-513. 1w . doi: 10.1111/hepr.12872.

D(Yamada S, Shimada M, Imura S, Morine Y, Ikemoto T, HI p 4 % H. Effective stepwise training and procedure standardization for young surgeons to perform laparoscopic left hepatectomy. *Surg Endosc*. 2017;31(6):2623-2629. 1w . doi: 10.1007/s00464-016-5273-3.

{ Yoshikawa M, Morine Y, Ikemoto T, Imura S, HI4 p 2 % H. Elevated Preoperative Serum CEA Level Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma Through the Epithelial-Mesenchymal Transition. *Anticancer Res*. 2017;37(3):1169-1175. 1w . DOI: 10.21873/anticancer.11430

D* Teraoku H, Morine Y, Ikemoto T, HI0 p 2 % H. Role of thrombospondin-1 expression in colorectal liver metastasis and its molecular mechanism. *J Hepatobiliary Pancreat Sci*. 2016;23(9):565-573. 1w . doi: 10.1002/jhbp.376.

10 13 6

q a , 7 , 3 % .+ % KS6: % ((+ p) (Sb2E6M%2) . 118 GI 2019.

- 118 G77 □ 5 □, 3 % . Epigallocatechin-3-gallate □ Nrf2 □ 2018.
- Navigation. □ 118 G77 □ 2018.
- 4 □, 4 % . (LED) □ 2018.5.26 □ .
- 6 □, 3 % . Nrf2 □ EGCG □ 56 G □ . 2018.
- 8 □, 3 % . ROS/ ERK pathway □ S2e, □ LED □ 117 G □ . 2017.
- 5 □, 5 % . Epigallocatechin-3-gallate (EGCG) □ Nrf2-Keap1 D □ 72 G □ . 2017. 5 □ .
- 7 □, 3 % . EOB-MRI is useful for 'one stop shop' modality based on functional liver volume. □ 29 G □ 6 G □ R □ . 2017.
- 8 □, 3 % . ROS/ ERK pathway □ S2e, □ LED □ 46 G □ . 2017.
- 5 □, 4 % . Adipose tissue derived stem cells □ Insulin-producing cells □ 53 G □ . 2017.
- 8 □, 8 % . HDAC □ 116 G □ . 2016.
- 6 □, 4 % . Insulin-producing cell □ 71 G □ . 2016.

0 6

0 6
0 6

0

4> 20)°

(1) 20,*
S !
& IMURA, Satoru>
\$7T
TM5
8 B 90380021

20(ã
& IKEMOTO, Tetsuya>
\$7T
TM5
8 B 20398019

20(≦(
& SAITO, Yu>
\$7T
TM
8 B 50548675

(2) 20,*

20
x 20 b 1. 20 c 20* b 0 \ 2i 8Z M0u 20 b
00 x 2i c 20 \ b 0 13... _ ö Y0 _ 6i M
IrM